Table of Contents
ISRN Obesity
Volume 2013, Article ID 390130, 9 pages
http://dx.doi.org/10.1155/2013/390130
Research Article

Youth, Caregiver, and Prescriber Experiences of Antipsychotic-Related Weight Gain

1College of Pharmacy and Department of Psychiatry, Dalhousie University, 5968 College Street, P.O. Box 15000, Halifax, NS, Canada B3H 4R2
2Department of Psychiatry and College of Pharmacy, Dalhousie University, QEII HSC, AJLB 7517, 5909 Veterans’ Memorial Lane, Halifax, NS, Canada B3H 2E2
3School of Population Health, University of Queensland, Herston, QLD 4006, Australia
4Department of Health and Wellness, Barrington Tower, P.O. Box 488, Halifax, NS, Canada B3J 2R8
5Dalhousie University, Department of Psychiatry, Dalhousie University/IWK Health Centre 5850 University Avenue, P.O. Box 9700, Halifax, NS, Canada B3K 6R8
6School of Nursing, Dalhousie University, 5869 University Avenue, P.O. Box 15000, Halifax, NS, Canada B3H 4R2

Received 23 July 2013; Accepted 29 August 2013

Academic Editors: S. Straube and G. S. H. Yeo

Copyright © 2013 Andrea Lynn Murphy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Alessi-Severini, R. G. Biscontri, D. M. Collins, J. Sareen, and M. W. Enns, “Ten years of antipsychotic prescribing to children: a Canadian population-based study,” Canadian Journal of Psychiatry, vol. 57, no. 1, pp. 52–58, 2012. View at Google Scholar
  2. R. R. Aparasu and V. Bhatara, “Antipsychotic prescribing trends among youths, 1997–2002,” Psychiatric Services, vol. 56, no. 8, article 904, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. W. O. Cooper, P. G. Arbogast, H. Ding, G. B. Hickson, D. C. Fuchs, and W. A. Ray, “Trends in prescribing of antipsychotic medications for US children,” Ambulatory Pediatrics, vol. 6, no. 2, pp. 79–83, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Goodwin, M. S. Gould, C. Blanco, and M. Olfson, “Prescription of psychotropic medications to youths in office-based practice,” Psychiatric Services, vol. 52, no. 8, pp. 1081–1087, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Harrison-Woolrych, J. Garcia-Quiroga, J. Ashton, and P. Herbison, “Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study,” Drug Safety, vol. 30, no. 7, pp. 569–579, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Olfson, C. Blanco, S. M. Liu, S. Wang, and C. U. Correll, “National trends in the office-based treatment of children, adolescents, and adults with antipsychotics,” Archives of General Psychiatry, vol. 69, no. 12, pp. 1247–1256, 2012. View at Google Scholar
  7. N. C. Patel, M. L. Crismon, K. Hoagwood et al., “Trends in the use of typical and atypical antipsychotics in children and adolescents,” Journal of the American Academy of Child and Adolescent Psychiatry, vol. 44, no. 6, pp. 548–556, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Pringsheim, D. Lam, and S. B. Patten, “The pharmacoepidemiology of antipsychotic medications for canadian children and adolescents: 2005–2009,” Journal of Child and Adolescent Psychopharmacology, vol. 21, no. 6, pp. 537–543, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Rani, M. L. Murray, P. J. Byrne, and I. C. K. Wong, “Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom,” Pediatrics, vol. 121, no. 5, pp. 1002–1009, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Schirm, H. Tobi, J. M. Zito, and L. T. de Jong-van den Berg, “Psychotropic medication in children: a study from the Netherlands,” Pediatrics, vol. 108, no. 2, article E25, 2001. View at Google Scholar · View at Scopus
  11. B. Vitiello, C. Correll, B. van Zwieten-Boot, A. Zuddas, M. Parellada, and C. Arango, “Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns,” European Neuropsychopharmacology, vol. 19, no. 9, pp. 629–635, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. J. M. Zito, D. J. Safer, L. T. W. de Jong-van den Berg et al., “A three-country comparison of psychotropic medication prevalence in youth,” Child and Adolescent Psychiatry and Mental Health, vol. 2, article 26, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. J. C. Seida, J. R. Schouten, K. Boylan et al., “Antipsychotics for children and young adults: a comparative effectiveness review,” Pediatrics, vol. 129, no. 3, pp. e771–e784, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. Canadian Adverse Reaction Newsletter, “Second-generation antipsychotics and cardiometabolic adverse reactions,” Canadian Adverse Reaction Newsletter, vol. 22, no. 1, 2012. View at Google Scholar
  15. T. Pringsheim, D. Lam, H. Ching, and S. Patten, “Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials,” Drug Safety, vol. 34, no. 8, pp. 651–668, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Panagiotopoulos, R. Ronsley, D. Elbe, J. Davidson, and D. H. Smith, “First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents,” Journal of the Canadian Academy of Child and Adolescent Psychiatry, vol. 19, no. 2, pp. 124–137, 2010. View at Google Scholar · View at Scopus
  17. T. Baptista, “Body weight gain induced by antipsychotic drugs: mechanisms and management,” Acta Psychiatrica Scandinavica, vol. 100, no. 1, pp. 3–16, 1999. View at Google Scholar · View at Scopus
  18. C. Deng, K. Weston-Green, and X.-F. Huang, “The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain?” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 34, no. 1, pp. 1–4, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Hosojima, T. Togo, T. Odawara et al., “Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia,” Journal of Psychopharmacology, vol. 20, no. 1, pp. 75–79, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. D. J. Müller, C. C. Zai, M. Sicard et al., “Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain,” Pharmacogenomics Journal, vol. 12, no. 2, pp. 156–164, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Palik, K. D. Birkás, G. Faludi, I. Karádi, and K. Cseh, “Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics,” Diabetes Research and Clinical Practice, vol. 68, supplement 1, pp. S60–S64, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Perez-Iglesias, I. Mata, J. A. Amado et al., “Effect of FTO, SH2B1, LEP, and LEPR polymorphisms on weight gain associated with antipsychotic treatment,” Journal of Clinical Psychopharmacology, vol. 30, no. 6, pp. 661–666, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. G. P. Reynolds, M. J. Hill, and S. L. Kirk, “The S-HT2C receptor and antipsychotic-induced weight gain—mechanisms and genetics,” Journal of Psychopharmacology, vol. 20, supplement 4, pp. S15–S18, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. M. N. Sicard, C. C. Zai, A. K. Tiwari et al., “Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis,” Pharmacogenomics, vol. 11, no. 11, pp. 1561–1571, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. L. Maayan, J. Vakhrusheva, and C. U. Correll, “Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis,” Neuropsychopharmacology, vol. 35, no. 7, pp. 1520–1530, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. S. K. Praharaj, A. K. Jana, N. Goyal, and V. K. Sinha, “Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis,” British Journal of Clinical Pharmacology, vol. 71, no. 3, pp. 377–382, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. D. B. Allison, J. L. Mentore, M. Heo et al., “Antipsychotic-induced weight gainaA comprehensive research synthesis,” American Journal of Psychiatry, vol. 156, no. 11, pp. 1686–1696, 1999. View at Google Scholar · View at Scopus
  28. M. Álvarez-Jiménez, O. Martínez-García, R. Pérez-Iglesias, M. L. Ramírez, J. L. Vázquez-Barquero, and B. Crespo-Facorro, “Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial,” Schizophrenia Research, vol. 116, no. 1, pp. 16–19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. B. Parsons, D. B. Allison, A. Loebel et al., “Weight effects associated with antipsychotics: a comprehensive database analysis,” Schizophrenia Research, vol. 110, no. 1–3, pp. 103–110, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. V. Simon, R. van Winkel, and M. de Hert, “Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review,” Journal of Clinical Psychiatry, vol. 70, no. 7, pp. 1041–1050, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. D. M. Taylor and R. McAskill, “Atypical antipsychotics and weight gain—a systematic review,” Acta Psychiatrica Scandinavica, vol. 101, no. 6, pp. 416–432, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. D. K. Raynor and D. Dickinson, “Key principles to guide development of consumer medicine information—content analysis of information design texts,” Annals of Pharmacotherapy, vol. 43, no. 4, pp. 700–706, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Álvarez-Jiménez, S. E. Hetrick, C. González-Blanch, J. F. Gleeson, and P. D. McGorry, “Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials,” British Journal of Psychiatry, vol. 193, no. 2, pp. 101–107, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. D. L. Foley and K. I. Morley, “Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis,” Archives of General Psychiatry, vol. 68, no. 6, pp. 609–616, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Gentile, “Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications,” Obesity Reviews, vol. 10, no. 5, pp. 527–542, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Maayan and C. U. Correll, “Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents,” Journal of Child and Adolescent Psychopharmacology, vol. 21, no. 6, pp. 517–535, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Álvarez-Jiménez, C. González-Blanch, B. Crespo-Facorro et al., “Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal,” CNS Drugs, vol. 22, no. 7, pp. 547–562, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. P. Benner, “Quality of life: a phenomenological perspective on explanation, prediction, and understanding in nursing science,” Advances in Nursing Science, vol. 8, no. 1, pp. 1–14, 1985. View at Google Scholar · View at Scopus
  39. N. Diekelmann, D. Allen, and C. Tanner, A Hermeneutic Analysis of the NLN Criteria for the Appraisal of Baccalaureate Programs. The NLN Criteria for Appraisal of Baccaiaureate Programs: A Critical Hermeneutic Analysis, National League for Nursing, New York, NY, USA, 1989.
  40. H. J. Streubert and D. R. Carpenter, Qualitative Research in Nursing. Advancing the Humanistic Imperative, Lippincott, Williams & Wilkins, Philadelphia, Pa, USA, 2003.
  41. R. B. Haynes, X. Yao, A. Degani, S. Kripalani, A. Garg, and H. P. McDonald, “Interventions to enhance medication adherence,” Cochrane Database of Systematic Rreviews, no. 4, Article ID CD000011, 2005. View at Google Scholar · View at Scopus
  42. J. A. Cramer, A. Roy, A. Burrell et al., “Medication compliance and persistence: terminology and definitions,” Value in Health, vol. 11, no. 1, pp. 44–47, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. G. D. C. Ball and L. J. McCargar, “Childhood obesity in Canada: a review of prevalence estimates and risk factors for cardiovascular diseases and type 2 diabetes,” Canadian Journal of Applied Physiology, vol. 28, no. 1, pp. 117–140, 2003. View at Google Scholar · View at Scopus
  44. D. C. W. Lau, J. D. Douketis, K. M. Morrison, I. M. Hramiak, A. M. Sharma, and E. Ur, “2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children,” Canadian Medical Association Journal, vol. 176, supplement 8, pp. S1–S13, 2007. View at Google Scholar · View at Scopus
  45. J. M. Jerrell and R. S. McIntyre, “Metabolic, digestive, and reproductive adverse events associated with antimanic treatment in children and adolescents: a retrospective cohort study,” Primary Care Companion to the Journal of Clinical Psychiatry, vol. 12, no. 4, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. V. Hamrin, E. M. McCarthy, and V. Tyson, “Pediatric psychotropic medication initiation and adherence: a literature review based on social exchange theory,” Journal of Child and Adolescent Psychiatric Nursing, vol. 23, no. 3, pp. 151–172, 2010. View at Publisher · View at Google Scholar
  47. R. Dent, A. Blackmore, J. Peterson et al., “Changes in body weight and psychotropic drugs: a systematic synthesis of the literature,” PLoS One, vol. 7, no. 6, Article ID e36889, 2012. View at Publisher · View at Google Scholar
  48. W. V. R. Vieweg, A. B. Sood, A. Pandurangi, and J. J. Silverman, “Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain?” Acta Psychiatrica Scandinavica, vol. 111, no. 3, pp. 177–184, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. A. J. Cameron, D. J. Magliano, and S. Soderberg, “A systematic review of the impact of including both waist and hip circumference in risk models for cardiovascular diseases, diabetes and mortality,” Obesity Reviews, vol. 14, no. 1, pp. 86–94, 2013. View at Publisher · View at Google Scholar
  50. S. Kodama, C. Horikawa, K. Fujihara et al., “Comparisons of the strength of associations with future type 2 diabetes risk among anthropometric obesity indicators, including waist-to-height ratio: a meta-analysis,” American Journal of Epidemiology, vol. 176, no. 11, pp. 959–969, 2012. View at Publisher · View at Google Scholar
  51. S. M. Haffner, “Relationship of metabolic risk factors and development of cardiovascular disease and diabetes,” Obesity, vol. 14, supplement 3, pp. 121S–127S, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Ho, C. Panagiotopoulos, B. Mccrindle, S. Grisaru, and T. Pringsheim, “Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth,” Journal of the Canadian Academy of Child and Adolescent Psychiatry, vol. 20, no. 3, pp. 234–241, 2011. View at Google Scholar · View at Scopus
  53. W. S. Leslie, C. R. Hankey, and M. E. J. Lean, “Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review,” QJM, vol. 100, no. 7, pp. 395–404, 2007. View at Publisher · View at Google Scholar · View at Scopus
  54. A. J. Mitchell, V. Delaffon, D. Vancampfort, C. U. Correll, and M. de Hert, “Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices,” Psychological Medicine, vol. 42, no. 1, pp. 125–147, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. Institute of Medicine (IOM), Living Well with Chronic Illness: A Call for Public Health Action, Academic Press, Washington, DC, USA, 2012.
  56. A. Mccloughen and K. Foster, “Weight gain associated with taking psychotropic medicationa: an integrative review,” International Journal of Mental Health Nursing, vol. 20, no. 3, pp. 202–222, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. A. D. Vandyk and C. Baker, “Qualitative descriptive study exploring schizophrenia and the everyday effect of medication-induced weight gain,” International Journal of Mental Health Nursing, vol. 21, no. 4, pp. 349–357, 2012. View at Publisher · View at Google Scholar